{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:26:57Z","timestamp":1788262017956,"version":"build-2803163510"},"reference-count":8,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.resinv.2019.03.011","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T09:15:40Z","timestamp":1557998140000},"page":"466-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria"],"prefix":"10.1016","volume":"57","author":[{"given":"Tadashi","family":"Sakaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Hataji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2019.03.011_bib1","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2019.03.011_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","article-title":"Therapeutic management options for stage III non-small cell lung cancer","volume":"8","author":"Yoon","year":"2017","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.resinv.2019.03.011_bib3","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.resinv.2019.03.011_bib4","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2019.03.011_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage \u2162 NSCLC","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2019.03.011_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.resinv.2019.03.011_bib7","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/1097-0142(19800601)45:11<2744::AID-CNCR2820451108>3.0.CO;2-U","article-title":"A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group","volume":"45","author":"Perez","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.resinv.2019.03.011_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/cancers10070222","article-title":"Radiation pneumonitis: old problem, new tricks","volume":"10","author":"Jain","year":"2018","journal-title":"Cancers"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534518302934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534518302934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:29:20Z","timestamp":1761949760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534518302934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2212534518302934"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2019.03.011","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2019.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}